Wire · opportunities
FDA sets cross-center framework for digital measures in clinical trials
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
The FDA has introduced a unified, cross-center framework for the use of digitally derived measures (DDMs) such as wearables and AI-enabled platforms in clinical trials, providing a structured pathway for evidence requirements based on the role of these digital endpoints. This framework reduces regulatory ambiguity, highlights the need for patient involvement, and emphasizes early engagement and scrutiny of AI algorithm credibility in clinical investigations.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 20 Aug 2026 and 21 Aug 2026.
◆ ◆ The Wire takeaway
You must engage early with the FDA before using wearable or AI-derived endpoints in trials as oversight is now coordinated across all medical product centers, closing previous regulatory gaps. Changes to digital device software mid-trial will no longer be easy to slip past regulators and need rigorous validation to avoid compliance risks.
◆ Coverage
2 sources · first reported 20 Aug 2026 · latest 21 Aug 2026
◆ Related on Wire
◆ Topics